RT Journal Article SR Electronic T1 Autoimmune profiling suggests paraneoplastic etiology in pediatric ROHHAD JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2021.06.04.21257478 DO 10.1101/2021.06.04.21257478 A1 Caleigh Mandel-Brehm A1 Leslie A. Benson A1 Baouyen Tran A1 Andrew F. Kung A1 Sabrina A. Mann A1 Sara E. Vazquez A1 Hanna Retallack A1 Hannah A. Sample A1 Kelsey C. Zorn A1 Lillian M. Khan A1 Lauren M. Kerr A1 Patrick L. McAlpine A1 Lichao Zhang A1 Frank McCarthy A1 Joshua E. Elias A1 Umakanth Katwa A1 Christina M. Astley A1 Stuart Tomko A1 Josep Dalmau A1 William W. Seeley A1 Samuel J. Pleasure A1 Michael R. Wilson A1 Mark P. Gorman A1 Joseph L. DeRisi YR 2021 UL http://medrxiv.org/content/early/2021/06/07/2021.06.04.21257478.abstract AB ROHHAD (Rapid-onset Obesity with Hypothalamic Dysfunction, Hypoventilation and Autonomic Dysregulation) is a rare, yet severe pediatric disorder resulting in hypothalamic dysfunction and frequent sudden death. Genetic and other investigations have failed to identify an etiology or diagnostic test. Frequent co-occurrence of neuroblastic tumors (NTs) and cerebrospinal fluid inflammation point to an autoimmune paraneoplastic neurological syndrome (PNS); however, specific anti-neural autoantibodies, a hallmark of PNS, have not been identified. Here, we screened antibodies from a curated cohort of ROHHAD patients (n=9) and controls (n=150) using a programmable phage display of the human peptidome (PhIP-Seq). Our ROHHAD cohort exhibited frequent association with NTs (8/9) and features consistent with autoimmune etiology. Autoantibodies to Zinc finger and SCAN domain-containing protein 1 (ZSCAN1) were discovered and orthogonally validated in 7 of 9 ROHHAD patients, all of whom had NTs, and shown to be absent in non-ROHHAD pediatric patients with NTs. Notably, human ZSCAN1 expression was confirmed in ROHHAD tumor and healthy human hypothalamus. Our results support the notion that tumor-associated ROHHAD is a pediatric PNS, potentially initiated by an immune response to peripheral NT. ZSCAN1 autoantibodies may aid in an accurate diagnosis of ROHHAD, thus providing a means toward early detection and treatment. Lastly, given the absence of the ZSCAN1 gene in rodents, our study highlights the value of human-based approaches in addition to the classical rodent-based approaches for detecting novel PNS subtypes.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research was supported by ROHHAD Fight Inc. the OMS Life Foundation the Repository Core for Neurological Disorders, Department of Neurology, Boston Childrens Hospital, and the IDDRC (NIH P30HD018655) and NIH R01MH122471. We would also like to acknowledge the New York Blood Center for contribution of healthy control plasma. Instituto Carlos III (ISCIII, PI20/00197 [JD]), and La Caixa Foundation (JD). CMA is supported by NIDDK (K23DK120899). Acknowledge the UCSF Nikon Core Facility for microscope imaging equipment and guidance. JDL is funded by a grant from Chan Zuckerberg Biohub. JDL, MRW, SJP and CMB are funded by the National Institute of Mental Health (NIMH) of the NIH (award 1R01MH122471-01). SJP, BT are also funded by the Brain Research Foundation (Scientific Innovations Award). CMB is also funded by The Emiko Terasaki Foundation (Project 7027742 / Fund B73335) and by the National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health (award 1K99NS117800-01). SEV is funded by the National Institute of Diabetes and Digestive and Kidney Diseases of the NIH (award 1F30DK123915-01).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All local IRB regulations were followed at Boston Children's Hospital protocol #09-02-0043 and University of California San Francisco protocol #13-12236All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData available within the article or its supplementary materials. Raw data files or original microscopy images available upon request.